[Eli Lilly GLP-1 drugs show significant weight loss] Pharmaceutical giant Eli Lilly announced the latest clinical trial results of GLP-1 drug Tirzepatide on its website on Thursday. Of the 938 adult subjects with overweight and type 2 diabetes, those who received 10 mg of Tirzepatide per week for 72 weeks lost an average of nearly 30 pounds, while those who received 15 mg a week lost an average of 34 pounds, comparable to surgery. Like Novo Nord's Wegovy, GLP-1 drugs are used to lose weight, not a panacea for "losing weight as soon as you eat them". Patients are still needed to cooperate to change their habits. If you stop taking drugs and return to bad living habits, weight gain is not to be expected.